## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 10.4% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($24.03)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Evercore ISI Remains a Buy on Beam Therapeutics (BEAM)**
- Source: The Globe and Mail | 20251209T180852 | Somewhat-Bullish | Relevance: 98%
-  Evercore ISI analyst Cory Kasimov maintained a Buy rating on Beam Therapeutics (BEAM) with a $35.00 price target. This re-affirms positive sentiment despite a recent Hold rating from TR | OpenAI â€“ 4o and negative insider sentiment. Beam Therapeutics reported a quarterly revenue of $9.7 million and a GAAP net loss of $112.73 million for the quarter ending September 30.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Evercore ISI Gr | $35 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.0x requires aggressive growth execution.
3. High short interest (23.2%, 9.3 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 7.04 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 23.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.04 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 13.2% to 10.4% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (10.4% > 10.0%), caution on chasing. MRS_5 at 1.4% confirms short-term momentum alignment. AM_20 at 12.7% shows strong absolute momentum above own 20MA. Outperforming sector by 12.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 10.42% (CS: 95) | Strong |
| RSI_14 | 60.0 | Neutral |
| MACD Histogram | 0.43 | Bullish |
| vs SMA20 | 1.126x | Above |
| vs SMA50 | 1.097x | Above |
| vs SMA200 | 1.311x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $27.51
- **Stop Loss:** $24.03 (12.6% risk)
- **Target:** $30.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 396
- **Position Value:** $10,893.96
- **Portfolio %:** 10.89%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*